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Abstract 
Conjugation of recombinant human deoxyribonuclease I (rhDNase) to polyethylene glycol 
(PEG) of 20 to 40 kDa was previously shown to prolong the residence time of rhDNase in the 
lungs of mice after pulmonary delivery while preserving its full enzymatic activity. This work 
aimed to study the fate of native and PEGylated rhDNase in the lungs and to elucidate their 
biodistribution and elimination pathways after intratracheal instillation in mice. In vivo 
fluorescence imaging revealed that PEG30 kDa-conjugated rhDNase (PEG30-rhDNase) was 
retained in mouse lungs for a significantly longer period of time than native rhDNase (12 days 
vs 5 days). Confocal microscopy confirmed the presence of PEGylated rhDNase in lung 
airspaces for at least 7 days. In contrast, the unconjugated rhDNase was cleared from the lung 
lumina within 24 hours and was only found in the lung parenchyma and alveolar macrophages 
thereafter. Systemic absorption of intact rhDNase and PEG30-rhDNase was observed. 
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However, this was significantly lower for the latter. Catabolism, primarily in the lungs and 
secondarily systemically followed by renal excretion of byproducts were the predominant 
elimination pathways for both native and PEGylated rhDNase. Catabolism was nevertheless 
more extensive for the native protein. On the other hand, mucociliary clearance appeared to 
play a less prominent role in the clearance of those proteins after pulmonary delivery. The 
prolonged presence of PEGylated rhDNase in lung airspaces appears ideal for its mucolytic 
action in cystic fibrosis patients. 
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Nowadays, therapeutic proteins account for more than half of the approved biopharmaceuticals 
and, considering their steady growth, their market share is likely to expand further in future 
years [1, 2]. Compared with traditional low molecular weight drugs, therapeutic proteins are 
endowed with higher potency and specificity, reduced toxicity and organ accumulation, and 
lower interaction with other drugs [3-7]. Despite obvious benefits for the topical treatment of 
respiratory diseases pulmonary delivery of therapeutic proteins is still in its infancy. Inhaled 
dornase alfa or , a mucolytic agent for the management of patients with cystic fibrosis (CF), 
was approved in 1993 and so far, remains the only therapeutic protein for inhalation in 
respiratory diseases on the market.  Several other therapeutic proteins are under development 
for the local treatment of lung diseases such as asthma, chronic obstructive pulmonary disease 
(COPD), lung infections, CF or alpha-1 antitrypsin deficiency; some are in advanced stages of 
clinical trials [8, 9].  
Proteins for inhalation face two major obstacles to successful clinical use in lung topical 
treatment: first, a likely physicochemical degradation during production, formulation, storage, 
and aerosolisation and, secondly, a short residence time in the airways [10]. Most proteins are 
indeed cleared from the lungs within 24 hours [11] due to the combination of effective clearance 
mechanisms, i.e., i) mucociliary transport towards the upper airways then elimination through 
the mouth and stomach, ii) absorption across lung epithelia into the systemic circulation, iii) 
both enzymatic and non-enzymatic degradation processes, and iv) uptake by lung cells, 
particularly alveolar macrophages [12-14]. 
Considerable efforts in the field of protein drug delivery are tailored towards increasing the 
half-life of short-acting proteins. A common way to achieve this goal is through conjugation to 
polymers, and polyethylene glycol (PEG) in particular, a strategy known as PEGylation. 
PEGylation, especially with high molecular weight (MW) PEGs, has proven successful in 
increasing the blood circulation time of proteins following injection by reducing their 
glomerular filtration in the kidneys, preventing enzymatic degradation, and decreasing 
immunogenicity [15-17].  
A few studies have demonstrated a long local residence time of PEGylated proteins in the lungs 
following their pulmonary delivery, especially for PEG ≥ 20kDa [10]. The residence times were 
reportedly extended to at least 48 hours for linear 20 kDa (PEG20) a1-proteinase inhibitor [18], 
2-arm 40 kDa PEG (PEG40) F(ab’)2 and PEG40 Fab’ antibody fragments compared with less 
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than 24 hours for their non-PEGylated counterparts [13, 19, 20]. The longer lung retention was 
accompanied by improved efficacy in small animal models [18, 19]. 
Dornase alfa or recombinant human deoxyribonuclease I (rhDNase) plays an essential role in 
the management of CF symptoms along with the current standard medications [21]. rhDNase 
decreases the viscoelasticity of respiratory secretions by cleaving the extracellular DNA 
primarily released by neutrophils into the airspaces [22]. However, the short residence time (< 
24 hours) of rhDNase in the lungs is a considerable drawback to its full clinical benefit [23]. 
Therefore, prolonging its residence time in the lungs would alleviate the burden of frequent and 
cumbersome administrations of the drug while maintaining or even enhancing its therapeutic 
efficacy, thereby improving patient’s life quality [10]. PEGylation of rhDNase was successfully 
performed with PEG20, PEG30, and PEG40 through site-specific conjugation to the N-terminal 
which allowed preserving the conformation and the full enzymatic activity of the protein [23, 
24]. 
In a recent publication, pharmacokinetic studies in healthy mice following intratracheal 
instillation showed that 30 and 40 kDa PEG conjugates of rhDNase were present in the lungs 
for more than 15 days. Unconjugated rhDNase, on the other hand, had a retention of less than 
24 hours. Furthermore, a single dose of PEG30-rhDNase or PEG40-rhDNase exhibited an 
equivalent DNA hydrolysis activity after 5 days as one daily dose of rhDNase during 5 days in 
β-transepithelial Na+ channel–overexpressing mice (β-ENaC) [25].   
Following pulmonary administration of proteins, their clearance from the lungs might involve 
the mucociliary escalator towards the mouth then gastrointestinal tract (GI tract), transport 
across respiratory epithelia towards the bloodstream, uptake by lung cells and alveolar 
macrophages, and catabolism [10]. The elimination of PEGylated proteins from the lungs by 
systemic absorption would mean a risk of systemic toxicity, while clearance into faeces is 
usually synonymous with a desirable safety profile. Since rhDNase cleaves extracellular DNA 
in the respiratory secretions of patients with CF, it is paramount to distinguish between the 
ratios of enzyme in lung parenchyma (unavailable) from those in airspaces, available to exert 
the intended mucolytic action.  
The purpose of the present work was to investigate the elimination pathways and fate of native 
and PEGylated rhDNase in the lungs following pulmonary delivery in mice. First, PEG20, 
PEG30, and PEG40 were site-specifically conjugated to rhDNase and then labelled with 
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different fluorochromes to be administered via intratracheal instillation. The fate of the native 
and PEGylated rhDNase compounds and PEG30 was then examined in the lungs using confocal 
microscopy. Finally, near-infrared fluorescence imaging (NIRF) was performed after 
administration of rhDNase and PEG30-rhDNase, either intratracheally or intravenously, to 
assess their in vivo biodistribution and elimination pathways.
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2. Material and Methods 
2.1. Materials 
Commercial recombinant human deoxyribonuclease I (rhDNase, Pulmozyme®) was obtained 
from Genentech, Inc. (South San Francisco, CA, USA). Linear methoxy PEG propionaldehyde 
of 20 kDa and 30 kDa and two-arm methoxy PEG propionaldehyde of 40 kDa (PEG20, PEG30, 
and PEG40, respectively) were obtained from NOF Corporation (Tokyo, Japan). Alexa Fluor™ 
488 TFP ester and Rhodamine B were purchased from Life Technologies (B.V., Gent, 
Belgium). MitoTracker® Red CMXRos, MitoTracker® Deep Red FM, and Draq5™ were 
purchased from Invitrogen™ (B.V., Gent, Belgium). Rhodamine-PEG30 was purchased from 
Creative PEGWorks (Winston Salem, NC, USA) with a degree of labelling (DOL) of 
Rhodamine ≥ 0.93. NHS-VivoTag-S ® 750 (VT750) was purchased from Perkin Elmer 
(Waltham, MA, USA). Unless otherwise mentioned, all other chemicals and reagents were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
2.2. PEGylation of rhDNase 
The PEGylation of rhDNase was adapted from the method described by Guichard et al. [23, 
25]. PEG20-rhDNase, PEG30-rhDNase, and PEG40-rhDNase were produced by conjugation 
of the N-terminal amino acid of rhDNase to PEG20, PEG30, and PEG40, respectively. 
Reductive amination in 0.1 M sodium acetate buffer (CH3CO2Na, pH 5) was performed using 
rhDNase at 10 mg/ml and a molar ratio PEG: rhDNase of 4:1 in the presence of sodium 
cyanoborohydride (NaBH3CN) as a reducing agent (100 molar excess). The reaction mixtures 
were stirred at room temperature overnight. The mono-PEGylated products were purified by 
anion exchange chromatography on a Resource Q, 1mL column with ÄKTA™ purifier 10 
system then by size exclusion chromatography (SEC) on a HiLoad 16/60 superdex 200 column 
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Purification and characterisation of 
mono-PEGylated products are shown in Figure S1. Native and PEGylated rhDNase products 
were stored at 4 °C in 150 mM NaCl, 1 mM CaCl2 as the marketed dornase alfa product, 
Pulmozyme®. 
2.3. Fluorescent labelling of rhDNase and PEGylated rhDNase 
Alexa Fluor™ 488 TFP ester was used for labelling rhDNase and PEGylated rhDNase products 
for confocal imaging experiments while NIR dye NHS-VivoTag-S ® 750 (VT750) was used 
for labelling rhDNase and PEG30-rhDNase for the biodistribution study by NIRF imaging. To 
this end, all solutions of rhDNase or PEG-rhDNases were exchanged against 1 mM CaCl2 in 
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phosphate buffer saline (PBS) by ultrafiltration using vivaspin® Turbo 4, 3 kDa (Sartorius; 
Stonehouse, Gloucestershire, UK). The appropriate volume of dye at 10 mg/ml in DMSO was 
then added to the protein solution at a molar ratio dye: protein of 10:1 and the reaction mixtures 
were kept at room temperature in dark under mild agitation for 1 h. The bulk of free dye was 
removed by ultrafiltration using vivaspin® Turbo 15, 10 kDa MWCO (Sartorius; Stonehouse, 
Gloucestershire, UK). Labelled rhDNase and PEGylated rhDNase were then further purified by 
SEC (HiLoad Superdex 200 pg, GE, Belgium), concentrated, filtered through 0.22 µm PVDF 
filters, and stored at 4 °C in a solution of 150 mM NaCl and 1 mM CaCl2 (Figure S2 and S3). 
The same degree of labelling (DOL) was achieved for all products (Table S1). The fluorescence 
signal of near-infrared labelled compounds was further verified by NIRF imaging (Figure S4). 
2.4. Confocal imaging of mouse lungs following intratracheal instillation of PEG30 and 
native and PEGylated rhDNases  
2.4.1.  Animals  
All experimental protocols were approved by the Institutional Animal Care and Use Committee 
of the Université catholique de Louvain (Permit number 2016/UCL/MD/019 and 
2019/UCL/MD/044). 6-week old Female RjOrl SWISS mice (Elevage Janvier, Le Genest-St-
Isle, France) were kept under conventional housing conditions and were allowed 1 week of 
acclimation before starting the experiments. Mice were fed a normal chow diet and had access 
to water ad libitum. 
For intratracheal instillation, mice were anaesthetised with ketamine/xylazine (90/10 mg/kg), 
while for in vivo imaging mice were anaesthetised by 1.5–2% isoflurane (Isoflutek™, Karizoo 
SA, Barcelona, Spain) in oxygen.  
2.4.2. Intratracheal instillation 
Mice were anaesthetised by intraperitoneal injection of ketamine/xylazine (90/10 mg/kg) then 
fixed on an inclined board (~45°) in a supine position using surgical tape. With the aid of a 
small laryngoscope (Penn-CenturyTM– Model LS-2, Philadelphia, USA), mice were intubated 
with a 20 G catheter (VWR International BVBA, Leuven, Belgium), then 30 ± 2 µl of samples 
or controls were administered intratracheally into the lungs using a precision syringe (100 µl, 
Model 710, Hamilton, Bonaduz, Switzerland) followed by an air bolus of 200 µl using 1ml 
syringe (HSW SOFT-JECT®, VWR International BVBA, Leuven, Belgium). Immediately 




2.4.3. Confocal imaging 
Mice were intratracheally instilled with 1 nmol of labelled compounds (A488-rhDNase, A488-
PEG20-rhDNase, A488-PEG30-rhDNase, or A488-PEG40-rhDNase). One nmol of 
Rhodamine B was used as a control to study the fate of the free dye. For this, Rhodamine B 
(MW ca. 0.48 kDa) was first dissolved in DMSO at 10 mg/ml then diluted to working solution 
of 16 µg/ml in 150 mM NaCl, 1 mM CaCl2. One nmol (30 µl of the working solution of 
Rhodamine B) was then intratracheally instilled to per mouse. Likewise, 1 nmol of Rhodamine-
PEG30 in 150 mM NaCl, 1 mM CaCl2 (30 µl of 1 mg/ml solution) was administered 
intratracheally per mouse.  
15 min (0.25 h), 4 h, 24 h, 48 h, 4 days, 7 days, or 15 days following administration, the mice 
were euthanised by cervical dislocation, and the lungs and tracheas were removed, roughly cut 
into ca. 2 mm slices by a razor blade then stained for confocal laser microscopy. Tissue was 
stained with MitoTracker® at 2 µM (MitoTracker® Red CMXRos or MitoTracker® Deep Red 
FM) and nuclei with either Draq5™ at 30 µM or Hoechst 33342 at 90 µM final concentration. 
All stains were prepared in 400 µl of 4% formaldehyde PBS solution then lung slices from the 
same mouse were dipped in the staining mixture for 15 min then transferred to 4% 
formaldehyde PBS solution until imaged. Slices were imaged within an hour using Cell 
Observer Spinning Disk (COSD, Zeiss, Germany) and were recorded in blue (405 nm), green 
(488 nm), red (561 nm), and far-red (635 nm) channels. All images were acquired at 25 
magnification and stored in 16-bit format. A laser exposure time of 200 ms was used throughout 
the experiments. 
Images were processed using ImageJ software (1.47v, NIH, USA). The detection threshold for 
compounds was set by choosing a cut-off so that to remove unspecific autofluorescence 
background (Figure S6A). 
2.5. Biodistribution of rhDNase and PEG30-rhDNase in mice after intratracheal 
instillation 
2.5.1. Longitudinal near-infrared fluorescence imaging study 
Mice (6-7 per group) were intratracheally instilled with 2 nmol of VT750-rhDNase, VT750-
PEG30-rhDNase, or VT750 (dye). Blank consisted of mice with no instillation. Three mice of 
each group were spared for the ex vivo study and the rest (3 to 4 mice) were imaged separately 
in dorsal and ventral positions at times 2-3 min, 15 min, 4 h, 8 h, and 24 h post-delivery, then 
every 1-3 days thereafter up to two weeks.  
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For the intravenous study, three mice per group were injected via the tail with 2 nmol of either 
VT750-rhDNase or VT750-PEG30-rhDNase (100 µl). Imaging was proceeded as above.  
All images were acquired by an IVIS Spectrum in vivo imaging system (PerkinElmer, France) 
using 2D epifluorescence mode at 745/800 nm (excitation /emission) with automated exposure 
time and binning. Living Image® software (PerkinElmer, France) was used for image 
acquisition and processing. The same regions of interest (ROIs) were consistently applied to all 
animals (Figure 2I). The same threshold and scale (minimum to maximum) were used for 
comparisons among groups. The baseline fluorescence values (autofluorescence) were 
estimated from a group of untreated mice (n ≥ 6) and were used to set the minimum threshold. 
2.5.2. Detection of rhDNase and PEG30-rhDNase in blood, urine and faeces 
Blood was collected from the tail using heparinised capillary tubes (60 µl haematocrit capillary, 
Hirschmann, Germany) at 2, 4, 8, and 24 h. Blood samples were imaged and ROIs were drawn 
around blood in microtubes. Blood samples were then centrifuged at 2500 rpm for 15 min to 
collect the plasma. Mice from different groups were housed in separate cages and the bedding 
was changed before instillation, 12 h, and 24 h post-delivery and faecal pellets were collected 
and imaged by IVIS Spectrum. Urines were collected at 2 h and when possible at 24 h by 
scuffing the mice against a metallic grid until urination then urines were collected by pipetting 
from a Petri dish placed underneath. Plasma and urines were frozen at -20 °C until further 
assayed. 
2.5.3. Ex vivo near-infrared fluorescence imaging 
Three mice of each group were sacrificed by cervical dislocation 24 h post-delivery. The blood 
was collected first via opened intracardiac puncture and the following organs were harvested 
and imaged ex vivo: lungs, liver, kidneys, heart, spleen, bladder, stomach, small and large 
intestines, and caecum. ROIs were drawn around organs placed in multiwall plates. Organs 
were frozen at -20 °C until further assayed. 
2.5.4. SDS-PAGE gel electrophoresis of samples 
Small pieces of lungs, liver, and kidneys were weighed and homogenised in 500 µl RIPA lysis 
buffer (Abcam, Cambridge, UK) using a tissue grinder (Polytron; Kinematica, Luzern, 
Switzerland). Tissue homogenates were then centrifuged at 4000 g at 4 °C for 10 min and the 
supernatants were stored at −20 °C. An amount of 15 µl of tissue homogenate was mixed with 
5 µl of loading buffer (4x Laemmli Sample Buffer, BioRad, Belgium) then the mixture was 
directly loaded onto SDS-PAGE gel (4–20% Mini-PROTEAN® TGX™ Precast Protein Gels, 
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BioRad, Belgium). Plasma (5 µl) and urine (≤ 30 µl) samples were first diluted in PBS if needed 
then loaded on the gel with loading buffer (3:1 sample: loading buffer). The gels were run at 
120 V for 60 min then imaged immediately by IVIS Spectrum. Known amounts of VT750-
rhDNase, VT750-PEG30-rhDNase, and VT750 were loaded on each gel as controls.  
2.5.5. Activity of rhDNase and PEG30-rhDNase in lung and liver homogenates 
The activity of rhDNase and PEG30-rhDNase in lung and liver homogenates was assessed 
using the methyl green (MG) assay described earlier [23, 26]. Briefly, the hydrolysis of the 
DNA-Methyl Green substrate (DNA-MG) by deoxyribonuclease releases free MG in solution, 
the colour of this latter fades out to colourless with time leading to a decreasing optical density 
(OD) at 620 nm.  
DNA-MG solution was prepared the day before by mixing 77% v/v of DNA from salmon testes 
at 2 mg/ml in buffer A (25 mM HEPES, 1 mM EDTA, pH 7.5), 4.6% of 0.4% w/v MG in buffer 
B (20 mM sodium acetate, pH4.2), and 18.4% of buffer C (25mM HEPES, 4 mM CaCl2, 4 mM 
MgCl2, 0.1% BSA, 0.01% thimerosal, 0.05% Tween20, pH 7.5). 
Lung and liver homogenates were first diluted in buffer C (40-fold and 80-fold respectively) 
then further serial 2-fold dilutions of samples and controls (100 µl) were prepared in buffer C 
in 96-well plates. 100 µl of DNA-MG solution was added to each well and the plates were 
sealed and incubated in a humid chamber at 37 °C for 24 h. At the end of incubation time, the 
absorbance was measured at 620 nm by SpectraMax i3 (Molecular Devices, US). 
2.6. Statistics  
ANOVA was used for multiple group comparisons (n ≥ 3). All data are presented as mean ± 
standard error of the mean (SEM). All statistical inferences are based on a two-sided 
significance level of * p < 0.05, ** p < 0.01, and *** p < 0.001 and were carried out using 




3. Results and discussion 
Previously published works have shown that conjugation of proteins to PEGs of MWs ≥ 20 kDa 
has a high potential for increasing their residence time in the lungs [13, 18-20, 27]. More 
recently, Guichard et al. demonstrated the prolonged residence time of 30 and 40 kDa PEG 
conjugates of rhDNase in the lungs of mice for more than 15 days compared to merely 24 h for 
the unconjugated rhDNase [25]. They also demonstrated the improved therapeutic efficacy of 
PEG30-rhDNase in β-ENaC mice, a model of the CF lung disease, as well as its safety after 
single and repeated administration to healthy mice. Here we investigated the biodistribution 
and clearance mechanisms of native and PEGylated rhDNase following pulmonary and 
intravenous delivery. We also showed the local fate in the lungs and provided insights into the 
degradation of native and PEGylated rhDNase. 
3.1. Lung local distribution of native and PEGylated rhDNase 
The local presence of rhDNase in airspaces is paramount for the mucolytic action of the enzyme 
and therefore its therapeutic efficacy. To assess the impact of PEGylation and PEG size on the 
local distribution of rhDNase in the lungs after pulmonary delivery, the fate of rhDNase, 
PEG20-rhDNase, PEG30-rhDNase, PEG40-rhDNase, PEG30, and Rhodamine was followed 
over time in mice by confocal microscopy. 
Shortly after intratracheal instillation (15 min), all compounds were distributed to most lobes 
and covered many regions of the lungs. In these regions, the signal distribution in airspaces was 
relatively homogenous and evenly filling the airspaces with no particular accumulation pattern 
(Figure 1 at 0.25 h, Figure S5). The fluorescence signal from the trachea was hardly detectable 
even at early time points; probably due to the presence of negligible amounts or washout of 
compounds during the staining step. The free dye was cleared very fast on account of its low 
MW (~ 0.48 kDa) and hydrophobic nature as no signal was detected at 4 h in either alveolar 
spaces or lung cells (Figure S6B). 
The signal intensity in airspaces decreased faster for rhDNase where the signal was barely 
detectable beyond 24 h except in alveolar macrophages and faintly in lung parenchyma. The 
PEGylated forms of rhDNase continued to be present in the airspaces for at least 4 days for 
PEG20-rhDNase and 7 days for PEG30-rhDNase and PEG40-rhDNase as well as PEG30 alone 
(Figures 1, S5, and S7). The fluorescent signal in alveolar macrophages was detected 4 h post 
instillation and persisted even after the disappearance of fluorescence from the airspaces. It 
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lasted 4 days for rhDNase and 15 days for PEG30-rhDNase, PEG40-rhDNase, and PEG30 
alone. 
 
Figure 1. Representative confocal imaging of rhDNase and PEG30-rhDNase in mouse lungs. 
One nmol of Alexa488-rhDNase or Alexa488-PEG30-rhDNase was administered by 
intratracheal instillation. Mice were sacrificed at specific time points and the lungs were sliced 
and stained with MitoTracker® for tissue and Draq5™ for nuclei. Sections were imaged with 
Cell Observer Spinning Disk (COSD, Zeiss, Germany). Compounds were pseudocoloured in 
green, tissue in magenta, and nuclei in blue. Each experimental condition was repeated at least 
twice. Lower right image shows the presence of PEG30-rhDNase in alveolar macrophages 
(arrows →), and alveolar spaces (stars *) at day 4 post-instillation. Images were processed by 
ImageJ software (1.47v, NIH, USA). Scale bars, 50 µm. 
 
The longer persistence of PEGylated rhDNase and PEG30 in alveolar macrophages compared 
with non-PEGylated rhDNase could be ascribed to the longer availability of the formers in the 
airspaces. They could also be taken up more slowly or be more resistant to degradation by 
alveolar macrophages [19, 27]. 
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Numerous alveolar macrophages are actively patrolling the alveolar spaces and engulfing 
therapeutic particles and proteins in the epithelial lining fluid, thus considerably limiting the 
efficacy of pulmonary drug delivery, unless they are themselves targeted [28-30]. We suggest 
that the PEGylation of rhDNase could lessen its uptake by alveolar macrophages and therefore 
contribute to the longer retention of PEGylated rhDNase in airspaces. Overcoming the barrier 
of macrophage uptake through surface coating of particles with PEG was indeed shown to 
increase their residence time in the lungs [31]. Along this line, depleting alveolar macrophages 
led to a significant increase in the systemic absorption of human chorionic gonadotropin (hCG, 
39.5 kDa) and IgG (150 kDa) after pulmonary administration in rats [32]. 
Macrophage uptake was also reported for PEG40-Fab’, PEG30-rhDNase, and PEGs of up to 
40 kDa after pulmonary delivery [19, 25, 27, 33]. While no quantitative data were collected in 
the present work, another study from our laboratory demonstrated that the uptake of PEGylated 
anti-IL13 Fab’ by alveolar macrophages was slightly less efficient than its non-PEGylated 
counterpart in mice [19]. In alignment with our observations, previous work published by 
Freches et al. concluded that PEGylation delayed the clearance of Fab’ fragment by alveolar 
macrophages and that the PEG40 moiety persisted longer than the Fab’ moiety inside the cells 
[27]. 
Protection against aggregation is another likely explanation for the lower uptake of PEGylated 
rhDNase. Indeed, because large proteins are poorly absorbed through the lungs, they are prone 
to aggregation and precipitation in lung lining fluid, thus, accelerating their uptake by alveolar 
macrophages [34]. However, stability studies in contact with bronchoalveolar lavage (BAL) 
revealed that PEGylation only confers slight protection to rhDNase against aggregation and loss 
of activity in the absence, but not the presence, of calcium ions (Figures S8 and S9). Therefore, 
a potential decrease in the uptake of PEGylated rhDNase by alveolar macrophages through 
preventing aggregation in lung lining fluid might not be significant.  
Furthermore, our data are consistent with previous work by Guichard et al. in which the increase 
in residence time of rhDNase was in accordance with the increased length of the PEG [25]. 
Bulkier PEGs could better protect proteins from aggregation and enzymatic degradation and 
reduce cell uptake and systemic absorption more efficiently [10, 25]. Patil et al. compared the 
lung retention of conjugated anti-IL-17A to PEG20 and PEG40 and nevertheless concluded that 
the PEG size did not affect the lung retention of anti-IL-17A to a large extent [13]. Finally, the 
fate of the PEG30 in mouse lungs was similar to that of the PEG30-rhDNase in terms of local 
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distribution pattern and retention time indicating that the fate of the PEG30-rhDNase in the 
lungs is highly influenced by the presence of the PEG moiety. 
3.2. Lung clearance of rhDNase and PEG30-rhDNase after pulmonary delivery 
Based on the confocal images and the previously published pharmacokinetic data of Guichard 
et al. demonstrating the effectiveness of PEG30-rhDNase in extending the presence of rhDNase 
in the lungs [25], we selected PEG30-rhDNase to carry out further biodistribution studies.  
For this purpose, the NIRF signal was followed overtime after the intratracheal instillation of 2 
nmol of VT750-rhDNase, VT750-PEG30-rhDNase or VT750 dye alone, in mice. As expected, 
the fluorescent signal was observed in the thorax immediately after instillation. The signal 
intensity from the ventral view was consistently higher than that from the dorsal view due to 
the shallower depth of the lungs from the former (Figure 2A-B). Despite being less intense, the 
signal from the dorsal view was less prone to interference with the signal from other organs 
especially at early time points (< 24 h). For instance, the fluorescent signals present in lungs, 
stomach and liver at 8 h post-instillation overlapped in the VT750-rhDNase group leading to 
an overestimation of the signal at this time point from a ventral view (Figure 2B). The 
contribution of other adjacent organs (i.e. the heart) to the in vivo apparent fluorescent signal in 
the thorax was negligible as was confirmed by ex vivo NIRF imaging at 24 h post-instillation 
(Figure 3A-B). It is worth mentioning that the apparent fluorescence signal detected from the 
lungs is underestimated compared with the signal from other relatively superficial or 
unprotected organs such as the liver, the stomach, and the bladder because the lungs are buried 
deep in the chest cavity. For instance, the dominant signal from the lungs at 24 h was only 
confirmed ex vivo (Figures 3A and B) while the in vivo images from the ventral view showed 
stronger signals from the bladder and the liver (Figure 2B). Therefore precautions should be 
taken when estimating relative organ distribution from live animals. Another significant 
drawback of the in vivo imaging is the presence of free dye and degraded proteins in lungs, 
blood, and other organs, which could bias interpretation of absorption and degradation based 
on in vivo imaging alone (see discussion below). Despite these artefacts, quantifications in live 
animals were useful in estimating the importance of mucociliary clearance and comparing organ 
distribution among groups as the in vivo data were in line with those obtained ex vivo for the 
lungs, liver, and digestive tract. 
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The fluorescence signal was present in the lungs up to 5-7 days for VT750-rhDNase and 12-14 
days for VT750-PEG30-rhDNase (Figure 2A-B), in clear contrast to the VT750 dye which was 
cleared within 24 h (Figure S10). 
Immediately after intratracheal instillation, the signal was observed in the lungs, trachea, mouth, 
and nose then rapidly spread throughout the whole body within 15 min indicating a systemic 
absorption of VT750-rhDNase, VT750-PEG30-rhDNase, and free VT750 dye (Figure 2B and 
Figure S10). The signal in the thorax ROI increased between time 2 min and 8 h. This artefact 
is ascribed to the increased signal in the blood over time, which gives rise to a higher apparent 
epifluorescence signal in the thorax ROI by NIRF imaging as blood vessels are located 
superficially beneath the surface of the skin, therefore, closer to the camera (Figure 2D). The 
signal in the thoracic region increased to an even higher level in the case of the VT750 dye 
which is absorbed more quickly due to its hydrophobic nature and low MW (i.e. 1.18 kDa vs 
37 or 67 kDa for rhDNase or PEG30-rhDNase, respectively). Geyer et al. reported similar 
findings after pulmonary delivery of 2.5 or 10 µg of Alexa-750-siRNA to mice [35]. In that 
study, the fluorescence signals in the thorax increased 6 and 24 h post-delivery compared to the 
initial measurements for the same mice. In our case, at 24 h post-delivery and beyond, the 
signals in the thorax were less than those initially measured (at 2-3 min) and that of VT750-
PEG30-rhDNase was 1.5 to 2-fold higher than that of VT750-rhDNase until total clearance 
from the lungs.  
3.3. Biodistribution of rhDNase and PEG30-rhDNase after intravenous delivery  
The biodistribution of rhDNase and PEG30-rhDNase after intravenous injection was also 
examined. Immediately after delivery, the signal was spread throughout the whole body 
confirming that a systemic absorption occurred after pulmonary delivery. In addition, as soon 
as 15 min after IV injection, a strong signal appeared in the bladder and the liver indicating a 
liver clearance and renal excretion of rhDNase and PEG30-rhDNase as degradation products, 
free dye, and intact proteins (Figure 2C), although the renal excretion of intact PEG30-rhDNase 
is unlikely (cf. 3.6). VT750-rhDNase did not persist in the liver for as long as VT750-PEG30-
rhDNase (5 days vs 22 days) (Figure 2G). Moreover, in vivo data did not reveal any significant 
distribution for both compounds in other organs including the lungs. The longer half-life and 
liver retention of PEGylated rhDNase were expected and are likely the result of the increased 
protein hydrodynamic size and thereby the reduced glomerular filtration. A delayed proteolytic 
degradation of PEGylated rhDNase is also possible [36-39].  
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3.4. Organ distribution of rhDNase and PEG30-rhDNase after pulmonary delivery 
Ex vivo imaging of organs at 24 h post-instillation clearly showed a dominant signal in the lungs 
for both VT750-rhDNase and VT750-PEG30-rhDNase groups compared to other organs 
(Figures 3A and B, Figures S11 and S12). The percentage of lung signal accounted for 91 ± 4% 
(mean ± SEM) of the total signal of harvested organs for VT750-PEG30-rhDNase compared 
with 66 ± 6% for VT750-rhDNase (Figure 3A and B). In addition, the total lung signal was 1.75 
times higher for VT750-PEG30-rhDNase compared with that of VT750-rhDNase, consistent 
with the in vivo imaging at 24 h post-instillation (Figures 2D, 3C and 3D). 
The signal in the liver peaked around 8 h and was roughly 8-fold higher in VT750-rhDNase 
group compared with VT750-PEG30-rhDNase at 24 h ex vivo (Figure 2E and Figure 3E). This 
is mainly attributed to the lower systemic absorption of VT750-PEG30-rhDNase preventing its 
significant accumulation in the liver and other distant organs. Higher signals were also detected 
in the heart for VT750-rhDNase compared with VT750-PEG-rhDNase (p < 0.05), but not in 
the kidneys, the spleen or the GI tract (Figure 3E). 
Clearance via the urine seemed to be predominant for all compounds as indicated by the 
presence of fluorescence signal in the bladder from early time points until the total clearance of 
compounds from the body (Figure 2B). Nevertheless, analysis of urines showed that most of 
the fluorescent signal stems from the free dye and degradation products rather than intact 
proteins (cf. 3.6). Due to the irregularity of urination, the signal from the bladder was not used 
for comparison among groups and the ex vivo signal in the kidneys was used instead (Figures 
3E and S11B). In contrast, no distinct signal from the kidneys could be obtained in live animals 





Figure 2. In vivo NIRF imaging in mice after intratracheal and intravenous administration. Swiss mice received 2 nmol of VT750-rhDNase, VT750-PEG30-rhDNase, or 
VT750 by intratracheal instillation (IT, A, B, and D-F). C and G, mice were injected intravenously (IV) via the tail with 2 nmol of VT750-rhDNase or VT750-PEG30-rhDNase. 
Blank mice did not receive any compound. Mice were imaged by IVIS Spectrum in 2D epifluorescence mode at 745/800 nm (ex/em). A and B, representative images from 
dorsal and ventral views, respectively after IT; D-F, quantification of ROIs in the thorax, liver, and stomach. C, representative images from ventral views after IV injection; G, 
quantification of ROIs in the liver. H, legend of figures D-G. I, ROI diagram. Data points represent the mean ± SEM of the total fluorescence signal (n = 3). Significant 
differences between VT750-rhDNase and VT750-PEG30-rhDNase are indicated by * for p < 0.05, ** for p < 0.01, and *** for p < 0.001 (repeated measures two-way ANOVA 




Figure 3. Ex vivo organ imaging in mice at 24 h post intratracheal instillation of 2 nmol of 
VT750-rhDNase, VT750-PEG30-rhDNase, or VT750 free dye. Mice were sacrificed, blood 
and organs were collected for epifluorescence quantification by IVIS Spectrum at 745/800 nm 
(ex/em). A and B represent the percentage of signal from each organ to the total signal from all 
organs for VT750-rhDNase and VT750-PEG30-rhDNase, respectively. C, NIRF images of 
lungs ex vivo and D, signal quantification ROIs in C. E, signal quantification in other organs, 
the GI tract signal is the sum signal from the stomach, small intestine, large intestine and 
caecum. Bar charts represent the mean ± SEM (n = 3). Significant differences are indicated by 




On the other hand, mucociliary clearance followed by digestive elimination appeared to 
contribute to the clearance of rhDNase and PEG30-rhDNase after pulmonary delivery but to a 
low extent and indifferently according to the compound. The fluorescence signal in the stomach 
was not detectable at early time points (< 15 min), in contradiction with an expected rapid 
accumulation of compounds initially deposited in the mouth during instillation (Figure 2F). It 
then built up to reach a maximum at 8 h suggesting mucociliary clearance followed by 
swallowing occurred. It is nevertheless noteworthy that fluorescence in the stomach was easier 
to spot in the VT750-PEG30-rhDNase group at 4 and 8 h as the signal from the liver did not 
interfere at these time points (Figure 2B 8 h). The signal in the faecal pellets collected up to 24 
h post instillation represented only a tiny fraction of the total signal (Figure S13) and that in the 
GI tract represented no more than 3% at 24 h with no difference between the VT750-rhDNase 
and PEG30-rhDNase groups (Figure 3E and Figure S14). 
These observations support Hastings et al. [14] who argued that the mucociliary clearance is 
not a significant mechanism of protein clearance from the lungs, particularly after delivery to 
distal airways [13]. Its contribution could be even less effective in respiratory diseases such as 
chronic obstructive pulmonary disease (COPD), CF, and asthma where the mucociliary 
clearance is impaired [40, 41]. 
The longer residence time of PEGylated rhDNase compared with rhDNase in the lungs is 
expected to be observed if compounds were administered by nebulisation or as dry powders. In 
the case of nebulisation, lung deposition is more homogeneous and peripheral compared to 
intratracheal instillation [42]; therefore, the systemic absorption and cell uptake of both proteins 
are expected to be higher by nebulisation but the involvement of mucociliary clearance would 
be undermined. In the case of dry powder inhalers, the clearance of solid particles is driven by 
their physico- chemical properties; once proteins are released from their carriers in contact with 
lung lining fluids, the longer residence time of PEGylated rhDNase compared to rhDNase 
would hold due to the lower absorption and cell uptake of the former.  
The pharmacokinetic advantages of PEGylated rhDNase are also expected to be observed in 
diseased CF lungs. Guichard et al. have shown that PEGylation increased the stability of 
rhDNase in CF respiratory secretions [24]. Moreover, the efficacy studies in β-ENaC mice 
showed that a single dose of PEG30-rhDNase or PEG40-rhDNase exhibited an equivalent DNA 
hydrolysis activity after 5 days as one daily dose of rhDNase during 5 days. These results 
suggest that PEGylated rhDNase was also retained longer in murine inflamed lungs [25]. 
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3.5. Integrity of rhDNase and PEG30-rhDNase in lung homogenates 
In a previous work [25], sustained retention of PEG30-rhDNase over 15 days in mouse lungs 
was reported, which agrees with the present data (Figure 2A-B). Nonetheless, the total clearance 
of unconjugated rhDNase from the lungs occurred within 24 h compared with 5 to 7 days in 
our experiments. To reconcile both findings, we suggest that the fluorescent signal detected for 
VT750-rhDNase in mouse lungs beyond 24 h might arise from degraded rhDNase in alveolar 
macrophages and lung parenchyma. Indeed, the signal followed by NIRF imaging originates 
not only from intact compounds but also from their degradation products and the released dye. 
It is well-established that the lungs are involved in protein metabolism, albeit to a lesser extent 
than the liver for example [34]. Moreover, for PEGylation to be effective as a method of 
improving the therapeutic efficacy of rhDNase, the enzymatic activity of PEGylated rhDNase 
should be preserved in vivo. It was therefore important to investigate the integrity and enzymatic 
activity of rhDNase and PEG30-rhDNase in the lungs. 
Gel electrophoresis of lung homogenates revealed the presence of distinct bands corresponding 
to the intact proteins as well as byproducts of VT750-rhDNase and VT750-PEG30-rhDNase at 
24 h (Figure 4A and B). The intensity of the bands corresponding to intact VT750-PE30-
rhDNase was 18.9 ± 1.0% of the total signal, 10-fold higher than that of VT750-rhDNase (1.8 
± 0.4%) (Figure 4A-C). This is in correlation with the 10-fold higher enzymatic activity on 
DNA of VT750-PEG30-rhDNase in lung homogenates compared with VT750-rhDNase 
(Figure 4D).  
Bands corresponding to the released VT750 dye and rhDNase fragments of roughly estimated 
MWs between 10 and 20 kDa were detected in lung homogenates for both VT750-rhDNase and 
VT750-PEG30-rhDNase groups (arrows in Figure 4A). Interestingly, no bands corresponding 
to the MW of rhDNase (~37 kDa) were visible for the VT750-PEG30-rhDNase group. The 
band observed just below that of VT750-PEG30-rhDNase likely corresponds to the same 
fragments of rhDNase (10-20 kDa) still attached to the PEG30 moiety (Figures 4A and B).  The 
most plausible explanation is that the degradation of the protein moiety in PEG30-rhDNase 
occurs first, while still attached to the PEG, which is then followed by the cleavage of the PEG 




Figure 4. Ex vivo analysis of lung homogenates 24 h post instillation of 2 nmol of VT750- 
rhDNase, VT750-PEG30-rhDNase, or VT750 (dye). A) SDS-PAGE of lung homogenates, 
arrows point to degradation fragments. B) Same image as A after concealing the bottom part of 
the gel and amplifying the signal to visualise VT750-rhDNase bands. Lane 1, Control loaded 
with VT750-rhDNase (~10 ng), VT750-PEG30-rhDNase, and VT750; Lanes 2-10, samples 
from different mice. Gel was imaged by IVIS Spectrum (745/800 nm ex/em). Scale in radiant 
efficiency ([p/s/cm²/sr] / [µW/cm²]). C) Percentage of signal intensities of intact bands to the 
total signal intensity of all bands in the same lane. D) Enzymatic activity of lung homogenates 
on DNA-MG substrate. E) Enzymatic activity of stock solutions of VT750-rhDNase and 
VT750-PEG30-rhDNase, showing their similar enzymatic activity. DNA hydrolysis releases 
MG in solution leading to a decrease in the absorbance at 620 nm after 24 h of incubation at 37 
°C. Data represent mean ± SEM (n = 3, t-test (C) and two-way ANOVA followed with Tukey's 
post hoc test (D-E), ** p < 0.01, and *** p < 0.001). MW, molecular weight. 
The degradation of the protein moiety of PEGylated proteins was demonstrated by Elliot et al. 
who followed the fate of PEG40-insulin in the plasma of rats after intravenous administration 
[43]. Using antibodies directed against PEG (anti-PEG) and insulin (anti-insulin), they detected 
the PEG moiety over a much longer period of time than insulin by Western blot but could not 
detect the native unmodified insulin, therefore, concluded that insulin was most likely degraded 
while still coupled to the PEG moiety, losing, thus, its antigenic epitopes. 
Our data suggest that PEG30-rhDNase suffered less degradation in the lungs and, therefore, 
retained more activity compared with rhDNase, which was extensively degraded at 24 h.  
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Taken together with the confocal images (Figure 1) and the pharmacokinetic data of Guichard 
et al. [25] in which rhDNase was cleared from the lungs within 24 h, it is likely that the intact 
fractions of rhDNase and PEG30-rhDNase in lung homogenates at 24 h are localised 
extracellularly whereas the intracellular signal observed in alveolar macrophages and epithelial 
cells by confocal imaging corresponds mostly to degraded fragments. 
3.6. Systemic absorption of rhDNase and PEG30-rhDNase after pulmonary delivery 
Systemic absorption to the bloodstream is another clearance mechanism of proteins from the 
lungs besides mucociliary clearance and local degradation. The systemic absorption of rhDNase 
after a single inhalation has been shown to range from less than 2% in monkeys up to 15% in 
rats [44]. Proteins of similar or larger MWs such as human chorionic gonadotropin (hCG, 39.5 
kDa), human albumin (68 kDa), and IgG (150 kDa) have also been reported to be absorbed into 
the blood after pulmonary delivery, albeit poorly [32, 34]. However, a few studies have reported 
a decrease in lung absorption of proteins upon their PEGylation. Following pulmonary delivery 
in rats, the bioavailability of recombinant human granulocyte-colony stimulating factor 
(rhGCSF, 18 kDa) dropped threefold after conjugation to 6 kDa PEG (11.9% to 4.5%) and even 
lower after conjugation to 12 kDa PEG (1.6%)[45]. A similar decrease was observed for 
IFNα2b (19 kDa), with its bioavailability reduced from 15% to 5.5% and < 0.4% when 
conjugated to PEGs of 12 kDa and 40 kDa, respectively [7]. Patil et al. showed that PEGylation 
of anti-IL-13 and anti-IL-17A (47 kDa) with PEG40 reduced both their uptake and transport 
across Calu-3 human lung epithelial cells [13]. Based on these studies and the general 
assumption that larger proteins are less absorbed from the lungs [7, 46], PEGylation was 
expected to diminish the absorption of rhDNase across the lung epithelial barrier.  
Systemic absorption of both VT750-rhDNase and VT750-PEG30-rhDNase was suspected from 
observations in live animals and isolated organs (Figure 2 and Figure 3). This was confirmed 
by monitoring the presence of the proteins in the blood. The maximum blood signals of VT750-
rhDNase were higher than those of VT750-PEG30-rhDNase (Figure 5A and Figure S15). The 
absorption of intact compounds was confirmed by the presence of bands corresponding to MWs 
of both intact VT750-rhDNase and VT750-PEG30-rhDNase in plasma by gel electrophoresis 
(Figure 5B). The signal of VT750-rhDNase in the blood peaked at around 4 h post-delivery 
then decreased slowly thereafter, whereas that of VT750-PEG30-rhDNase increased initially 
then remained relatively steady from 2 h to 24 h. The signal intensity patterns of VT750-
rhDNase and VT750 PEG30-rhDNase bands in plasma were overall in agreement with the 
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signals from the whole blood. However, the signal in the blood from 4 h onwards might be 
influenced more by the presence of free dye and degradation products rather than intact 
proteins. Indeed, besides the free dye detected in all groups, faint bands corresponding to 
degraded fragments of VT750-rhDNase and VT750-PEG30-rhDNase similar to those detected 
in lung homogenates at 24 h were detected in plasma between 4 h and 24 h (Figure 5B). These 
degradation fragments likely diffused from the lungs into the systemic circulation. However, 
degradation of VT750-rhDNase and VT750 PEG30-rhDNase could also have occurred in 
plasma, liver or other tissues after systemic absorption.  
Gel electrophoresis of urine samples collected 2 h after intratracheal instillation showed the 
presence of intact VT750-rhDNase but not VT750-PEG30-rhDNase (Figure 5C). Renal 
excretion of VT750-rhDNase is expected to be relatively rapid due to the low MW of rhDNase 
compared with the threshold of renal filtration (60-70 kDa) [39, 47-50]. On the other hand, no 
traces of intact VT750-PEG30-rhDNase could be detected in the urine at 2 h and 24 h, likely 
due to its large molecular volume (Figure 5C and Figure S16). Our measurements of the 
hydrodynamic size of rhDNase and PEG30-rhDNase by dynamic light scattering indicate a size 
of ~ 4.8 nm for rhDNase and ~10 nm for PEG30-rhDNase (Table S2). The hydrodynamic size 
of the latter is larger than that of serum albumin (68 kDa, ~ 6 nm), a protein of similar MW 
[51]. It is known that the molecular size of PEGylated proteins is much larger than proteins of 
similar MWs [39, 52]. In fact, the hydrodynamic volume of PEG 18 kDa alone is greater than 
that of serum albumin [53]. Therefore, the renal filtration of intact PEG30-rhDNase should in 
principle be negligible. It is worthwhile to mention that PEGs as big as 40 kDa were shown to 
be excreted in the urines of mice, rats, and humans [54-56].  
No bands of either VT750-rhDNase or VT750-PEG30-rhDNase could be detected in the 
kidneys which could be also explained by the weak signal obtained in the kidneys ex vivo at 24 
h (Figure S17). Only degraded fragments of VT750-rhDNase were detected in the liver for 
VT750-rhDNase group at 24 h, suggesting the potential implication of the liver in the 
catabolism of the protein after absorption from the lung. On the other hand, the signal intensity 




Figure 5. Analysis of blood, plasma, and urine by NIRF imaging. Mice received 2 nmol of VT750-
rhDNase, VT750-PEG30-rhDNase, or VT750 by intratracheal instillation (IT, A-C) or intravenous 
injection (IV, D and E). A, D) Quantification of signal in blood samples collected at 2, 4, 8, and 24 h 
post-delivery by IVIS Spectrum at 745/800 nm (ex/em). B) SDS-PAGE of plasma (5 µl) at 2, 4, and 24 
h post-instillation. C) SDS-PAGE of urines (30 µl) collected at 2 h post-instillation. E) SDS-PAGE of 
plasma (5 µl) at 2 and 24 h post-injection. Arrows point to degradation fragments. Samples were mixed 
with loading buffer (3:1 sample: 4x Laemmli) then loaded on the gel (4–20%) and run at 120 V for 60 
min. Lane 1, Control loaded with VT750-rhDNase (~10 ng), VT750-PEG30-rhDNase, and VT750; 
Samples from different mice are in lanes 2-8 (B), 2-10 (C), or 2-7 (E). Gels were imaged by IVIS 
Spectrum (745/800 nm ex/em). Scale in radiant efficiency ([p/s/cm²/sr] / [µW/cm²]). Data points 
represent the mean ± SEM (n = 3). Significant differences from VT750-rhDNase are indicated by *** 
p < 0.001 for VT750-PEG30-rhDNase and ### p < 0.001 for VT750 (two-way ANOVA followed with 




3.7. Elimination of rhDNase and PEG30-rhDNase after intravenous delivery  
After IV injection, VT750-rhDNase was cleared from the blood faster than VT750-PEG30-
rhDNase (Figure 5D). Plasma concentrations of VT750-rhDNase were already lower than those 
of VT750-PEG30-rhDNase at 2 h and were barely detectable at 24 h (Figure 5D-E). Gel 
electrophoresis of plasma collected 4 h and 24 h post-injection showed similar degradation 
products for both VT750-rhDNase and VT750-PEG30-rhDNase (Figure 5E). These 
degradation products are also similar to those found in the plasma 24 h post-instillation (Figure 
5B). This confirms our earlier suggestion that further degradation in the plasma, liver, or other 
tissues could occur following systemic absorption of both intact and degraded rhDNase and 
PEG30-rhDNase from the lungs.  
4. Conclusions 
In this work, the fate in the lungs and elimination pathways of native and PEGylated rhDNase 
were investigated following intratracheal delivery to healthy mice. Native rhDNase was cleared 
from the lungs within 24 h whereas conjugation to PEGs of 20 to 40 kDa sustained the presence 
of the enzyme in lung airspaces for more than 4 days (PEG20-rhDNase) or 7 days (PEG30-
rhDNase and PEG40-rhDNase) after a single dose. Reduced degradation within the lungs and 
lower systemic absorption were identified as major mechanisms driving the longer retention of 
PEGylated rhDNase in the lungs. Both rhDNase and PEG30-rhDNase were primarily degraded 
in the lungs and secondarily in the blood, liver, or other tissues, followed by renal excretion of 
byproducts. Interestingly, the degradation of PEG30-rhDNase likely involves an initial 
fragmentation of the protein followed by a detachment of the PEG moiety. Following 
intratracheal instillation, no accumulation of the proteins was seen in other organs at the 
exception of rhDNase in the liver. However, liver accumulation was prominent after IV 
injection and was more marked for PEG30-rhDNase. Alveolar macrophages were shown to 
actively take up both PEGylated and native rhDNase as well as PEG alone. More in-depth 
mechanistic studies are being conducted to determine the influence of PEGylation on the uptake 
by macrophages, the transport across lung epithelial cells, and the interaction with respiratory 
mucus. Overall, the prolonged presence of PEGylated rhDNase in lung airspaces would be ideal 
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